TERNS PHARMACEUTICALS

Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701

14 May 2025 06:30:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

08 May 2025 13:05:01 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

02 May 2025 13:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals to Participate in The Citizens Life Sciences Conference

30 Apr 2025 13:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Inducement Grant to New Employees Under Nasdaq Listing Rule 5635(C)(4)

02 Apr 2025 13:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

20 Mar 2025 13:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(C)(4)

26 Feb 2025 13:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45th Annual Healthcare Conference

25 Feb 2025 05:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer

24 Feb 2025 13:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Appoints Robert Azelby to Board of Directors

20 Feb 2025 13:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

05 Feb 2025 13:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

03 Feb 2025 13:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference

08 Jan 2025 13:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

02 Jan 2025 13:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Announces Positive Early Data from Phase 1 CARDINAL Trial of TERN-701 for Chronic Myeloid Leukemia

03 Dec 2024 04:00:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

02 Dec 2024 13:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors

18 Nov 2024 13:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Third Quarter 2024 Financial Results and Corporate Updates

12 Nov 2024 13:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences

06 Nov 2024 13:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

07 Oct 2024 13:05:00 By Nasdaq GlobeNewswire